AP-0105 (PRESent-5)
Проводит ApcinteX Ltd
Страница компанииA Global, Non-interventional Study to Prospectively Evaluate Bleeding Episodes and Treatment Use in Patients with Hemophilia
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование прекращено досрочно, новых участников не набирают.
- Возраст участников: 12–65 лет, только мужчины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 108 чел. во всех странах исследования.
- Плановая дата окончания (11.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 14
Критерии включения
- Male participants greater than or equal to (>=) 12 and less than or equal to (<=) 65 years of age
- Who are capable of providing written informed consent (adolescent assent and parental/guardian consent when appropriate) for participation after reading the information and consent form and having the opportunity to discuss the study with the Investigator or their designee
- With historically documented severe HemA (defined as factor VIII \[FVIII\] less than (<) 0.01 International Units per milliliter (IU/mL) \[<1 percent {%}\]), with or without inhibitors, or moderately severe to severe HemB (defined as factor IX \[FIX\] <=0.02 IU/mL \[<=2%\]) without inhibitors. Participants must be currently included in a prophylactic treatment program or if undergoing an on-demand treatment regimen must have had >=6 documented acute bleeding episodes (spontaneous or traumatic) that required coagulation factor infusion during the 6 months before enrollment OR: Historically documented HemB (defined as FIX <=0.05 IU/mL \[<=5%\]) with inhibitors with a historical or ongoing high titer inhibitor \[>=5 Bethesda Units/mL\] based on medical records or laboratory reports) and an ABR of >=6 in the 6 months before enrollment
- Who are able to use a diary to document bleeding events and associated treatment
Критерии невключения
- With known thrombophilia
- With body weight greater than (>)150 kilogram (kg) or body mass index >40
- With known current inadequate hematologic function (eg, platelet count <100,000 per microliter \[/mcL\] and/or hemoglobin level <10 grams per deciliter \[g/dL\], <100 g/L), hepatic function (that is, total bilirubin >1.5*upper limit of normal \[ULN\] \[excluding Gilbert syndrome\], aspartate transferase and/or alanine aminotransferase levels >3*ULN; clinical signs or known laboratory or radiographic evidence consistent with cirrhosis of the liver) or renal function (that is, serum creatinine >2*ULN; based on medical records or available laboratory reports)
- With previous deep vein thrombosis and pulmonary embolism, myocardial infarction, or stroke
- With history of intolerance to subcutaneous injections
- With known current uncontrolled hypertension (systolic blood pressure >160 millimeter of mercury (mm Hg); diastolic blood pressure >100 mm Hg; based on medical records)
- With active cancer or requires therapy for cancer, except for basal cell carcinoma
- With concurrent participation in an interventional clinical trial
- With current or planned use of emicizumab
- With prior, ongoing, or planned treatment with gene therapy for hemophilia
- With history of or other evidence of recent alcohol or drug abuse as determined by the Investigator or their designee (in the 12 months before enrollment)
- With known Human Immunodeficiency Virus (HIV) infection with CD4 count (or T-cell count) of <200 cells/mcL within 24 weeks before enrollment
- With current or planned treatment with anticoagulant or antiplatelet drugs
- With any other significant conditions or comorbidities that, in the opinion of the Investigator or their designee, would make the participant unsuitable for enrollment
Источник: ClinicalTrials.gov, NCT05605678 · запись обновлена в реестре 7 февраля 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (2)
- Annualized Bleeding Rate (ABR) for Treated Bleeds and All Bleeds — Minimum 12 weeks
- Average Dose (IU/kg) of Associated Treatment Received for Bleeding Episodes per Hemophilia Product per Time Period and per Bleeding Episode — Minimum 12 weeks
Цель исследования
The primary objective of this study is to obtain prospective baseline documentation of annualized bleeding rates (ABRs) and treatment under standard-of-care (SOC) therapy among participants with hemophilia A or B. Participants in the study may be eligible to enroll in future planned interventional studies to be conducted by Sponsor.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05605678 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.